Current research efforts are being conducted in collaboration with the National Cancer Institute, the Gynecologic Oncology Group and various industry sponsored protocols to offer our patients the opportunity to participate in cutting edge research. Our research protocols include first line treatment for those patients newly diagnosed with gynecologic malignancies as well as trials for those diagnosed with recurrent or progressive disease. Currently available clinical trials are geared towards ovarian, endometrial and cervical carcinomas.
Each protocol offers patients standard of care treatment along with investigational products that have shown promise in the treatment of cancer. PARP inhibitors, HER2 pathway blockers, anti-VEGF and investigational chemotherapies are being utilized. A Phase I vaccine trial in advanced epithelial and ovarian cancer is also being launched. Tissue acquisition at the time of a patient’s initial surgery is another area of research that may offer benefit to the patient by offering specific treatment tailored to the genetic typing of the tumor. This tissue can be sent for chemotherapy sensitivity and/or molecular profiling in an effort to help individualize therapy.
Current Protocols
|
Research Protocols |
|||||
|
Principal Investigator |
Phase |
Cancer Type |
Stage |
Study Name |
Study Title |
|
Dr. John Elkas |
III |
Peritoneal, Ovarian, Fallopian Tube |
III/IV |
GOG0212 |
A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or xyotax versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy. |
|
Dr. John Elkas |
I |
Ovarian, Endometrial |
I-IV |
E39 |
Phase Ib trial of folate binding protein (FBP) peptide (E39) vaccine in ovarian and endometrial cancer patients. |
|
Dr. John Elkas |
N/A |
N/A |
N/A |
Tissue Study |
Tissue and data acquisition for the study of gynecologic disease. |
|
Dr. John Elkas |
N/A |
All |
All |
ChemoFX |
A non-interventional, longitudinal, multi-center initiative examining outcomes associated with the use of the ChemoFx Assay in solid tumor malignancies. |
|
Dr. von Pechmann |
N/A |
All |
Not specified |
ChemoBladder |
Natural history of urinary symptoms in women receiving paclitaxel/carboplatin for treatment of gynecologic cancers. |
|
Dr. von Pechmann |
N/A |
N/A |
N/A |
MELS |
Mesh erosion in laparoscopic sacrocolpopexy. |
|
Dr. John Elkas |
N/A |
N/A |
N/A |
GSA |
In vitro evaluation of binding of optical imaging compounds to human epithelial ovarian adenocarcinoma tissue specimens. |
|
Dr. Annette Bicher |
N/A |
N/A |
N/A |
Caris Registry |
A registry of the Target Now test results (biomarker expression patterns) for evaluation of correlation with clinical outcomes for cancer patients. |
